Introduction

Skeletal muscle aging (sarcopenia) is the key feature of age-related degenerative disease, which is characterized by skeletal muscle loss and function degeneration. Patients with sarcopenia present with 0.5%--1% muscle loss per year, which may be related to cachexia and other underlying malignant diseases.[@b1-cia-13-2407] A previous study conducted in the UK among people with an average age of 67 years suggested that the incidence of sarcopenia was 4.6% in men and 7.9% in women.[@b2-cia-13-2407] Another study reported that the incidence of sarcopenia was 36.5% in people with an average age of 70.1 years in the USA.[@b3-cia-13-2407] As the population ages, the incidence of sarcopenia will be highlighted. Therefore, it is necessary to explore the mechanism of age-related sarcopenia.

Contributions have been made to characterize the mechanism associated with age-induced muscle loss. It is reported that age-related muscle loss and function reduction may be due to the abnormal production of aging cells and sensitivity to cytokines.[@b4-cia-13-2407] Mitochondrial dysfunction is an event in muscle aging and contributes to muscle mass loss and aerobic function decline.[@b5-cia-13-2407] The superoxide generated by mitochondria is accumulated in aged cells and plays a contributory role in muscle aging.[@b6-cia-13-2407] Muscle aging is associated with reduced Ca^2+^ homeostasis, and Ca^2+^ spark signaling appeared to be suppressed in aged skeletal muscles.[@b7-cia-13-2407] In addition, Hall et al[@b8-cia-13-2407] found that myofiber-associated satellite cells showed self-renewal capabilities and the transplantation of these cells was proposed to prevent skeletal muscle aging. However, the mechanism of skeletal muscle aging has not yet been clarified. miRNAs are a class of small noncoding RNAs and have been reported to play a role in the aging process.[@b9-cia-13-2407],[@b10-cia-13-2407] Accumulating evidences have confirmed that miRNAs play a crucial role in the age-related changes in skeletal muscle mass, composition, and function.[@b11-cia-13-2407]--[@b13-cia-13-2407] Moreover, some miRNAs are identified to be regulated with age and may be linked to key regulators of muscle protein synthesis and regeneration in young and old skeletal muscle.[@b14-cia-13-2407] Despite these, the potential miRNAs involved in skeletal muscle aging have been fully reported.

In the present study, we analyzed the differentially expressed miRNAs between the young and old muscle samples, followed by function and pathway enrichment analysis. We aimed to explore the involvement of miRNAs in the potential mechanisms of muscle aging and provide new perspectives for the prevention of muscle aging.

Materials and methods
=====================

miRNA expression data
---------------------

The miRNA expression profile of human skeletal muscle (GSE23527)[@b15-cia-13-2407] was downloaded from Gene Expression Omnibus (GEO) database. There were a total of 36 skeletal muscle samples: 19 from young male subjects and 17 from old male subjects. The data from 12 old and 12 young skeletal muscle samples were produced based on the GPL10358 platform, and the remaining data from 5 old and 7 young skeletal muscle samples were produced based on the GPL10415 platform.

Data preprocessing and differentially expressed miRNA analysis
--------------------------------------------------------------

The raw data were processed by limma package (version 3.10.3)[@b16-cia-13-2407] in R (version 3.3.2), including background correction and expression profile normalization.

After preprocessing, differentially expressed miRNAs between the young and old samples based on the two platforms were analyzed by unpaired *t*-test through limma package, respectively. *P*\<0.05 and log fold change (log FC) \>1 were set as the cutoff values. All the differentially expressed miRNAs were pooled for further analysis.

Prediction of miRNA targets
---------------------------

The target genes of differentially expressed miRNAs were retrieved from DIANA-microT, MicroInspector, miRanda, MirTarget2, miTarget, NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and TargetScan/TargertScanS databases using the miRecords[@b17-cia-13-2407] tool. The miRNA--target gene interactions deposited in at least five databases were collected. The miRNA--target gene network was constructed by Cytoscape version 3.2.0[@b18-cia-13-2407] (<http://www.cytoscape.org/>).

Function and pathway enrichment analysis of miRNA targets
---------------------------------------------------------

Target genes of upregulated and downregulated miRNAs were subjected to Gene Ontology (GO)[@b19-cia-13-2407] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway[@b20-cia-13-2407] enrichment analysis. The target genes were annotated to GO biological process (BP) terms by DAVID version 6.8 online tool[@b21-cia-13-2407],[@b22-cia-13-2407] (<https://david.ncifcrf.gov/>). The pathways that were closely related to miRNA targets were analyzed by clusterProfiler[@b23-cia-13-2407] package. *P*\<0.05 was set as the threshold value.

Protein--protein interaction (PPI) network analysis
---------------------------------------------------

The miRNA--target gene interactions were predicted by using the STRING database version 10.0[@b24-cia-13-2407] (<http://www.string-db.org/>). The gene interaction pairs with the PPI score of ≥9 were collected for PPI network construction using Cytoscape version 3.2.0. The significant modules with the score of \>10 were mined using the MCODE plugin[@b25-cia-13-2407] of the Cytoscape software. The module genes were subjected to KEGG pathway analysis with the criteria for significance set as *P*\<0.05.

Transcriptional factor (TF) prediction for target genes
-------------------------------------------------------

The TF--target gene interactions in the PPI network were predicted by iRegulon plugin version 1.3[@b26-cia-13-2407] (<http://apps.cytoscape.org/apps/iRegulon>). Minimum identity between orthologous genes was set as 0.05, and the maximum false discovery rate on motif similarity was set as 0.001. The TF--gene interaction pairs with normalized enrichment score (NES) of \>4 were used for TF regulatory network construction.

Sample collection
-----------------

Five patients with sarcopenia and five cases without sarcopenia were enrolled from the First Hospital of the Jilin University. The skeletal muscle samples were collected via orthopedic surgery. All the patients provided written informed consent to participate in this study, and approval was obtained from the ethics committee of the First Hospital of Jilin University.

RNA isolation and real-time quantitative PCR (RT-qPCR) analysis
---------------------------------------------------------------

Total RNA was isolated from 100 mg tissue samples using TRIZOL regent (Thermo Fisher Scientific, Waltham, MA, USA) for further analysis. RNA quality was determined by an Infinite M100 PRO microplate reader (Tecan, Crailsheim, Germany). cDNA was reverse transcribed from a total of 5 µg of RNA by PrimeScript™ RT Master Mix, according to the manufacturer's instructions. RT-qPCR was performed, with a reaction volume of 20 µL, including 10 µL of the SYBR Premix EX Taq (2×), 1 µL of forward primer, 1 µL of reverse primer, and 8 µL of cDNA. The primer sequences are summarized in [Table 1](#t1-cia-13-2407){ref-type="table"}. The PCR reaction conditions used were as follows: 50.0°C for 3 minutes, 95.0°C for 3 minutes, followed by 40 cycles of 95.0°C for 10 seconds and 60.0°C for 30 seconds.

Statistical analyses
--------------------

All the data were expressed as mean ± SD and analyzed by the SPSS 22.0 software (IBM Corporation, Armonk, NY, USA). *P*\<0.05 was considered significant.

Results
=======

Differentially expressed miRNAs
-------------------------------

Based on the GPL10358 platform, there were 12 differentially expressed miRNAs between the young and old samples, including six downregulated miRNAs and six upregulated miRNAs. In addition, 11 miRNAs were found to be differentially expressed between the young and old samples based on the GPL10415 platform, including five upregulated miRNAs and six downregulated miRNAs ([Table 2](#t2-cia-13-2407){ref-type="table"}). All the differentially expressed miRNAs were pooled for further analysis.

miRNA--target gene regulatory network
-------------------------------------

A total of 1,236 miRNA--target gene interaction pairs were obtained through miRecords, which contained six upregu-lated miRNAs (hsa-miR-34a, hsa-miR-449b, hsa-miR-215, hsa-miR-499-5p, hsa-miR-184, and hsa-miR-450a) and six downregulated miRNAs (hsa-miR-19a, hsa-miR-144, hsa-miR-532-5p, hsa-miR-365, hsa-miR-487b, and hsa-miR-362-5p). The miRNA--target gene regulatory network is illustrated in [Figure 1](#f1-cia-13-2407){ref-type="fig"}. The significant nodes in this network included hsa-miR-19a (degree =434), hsa-miR-34a (degree =217), hsa-miR-144 (degree =227), and hsa-miR-532-5p (degree =166). Significant pathways that were closely related to significant miRNAs are shown in [Figure 2](#f2-cia-13-2407){ref-type="fig"}. Notably, has-miR-19a was significantly enriched in the AMP-activated protein kinase (AMPK) signaling pathway (protein kinase AMP-activated catalytic subunit alpha 1 \[PRKAA1\] and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 \[PFKFB3\]), and has-miR-34a was significantly enriched in cellular senescence (sirtuin 1 \[SITRI\] and cell division cycle 25A \[CDC25A\]) and mitogen-activated protein kinase (MAPK) signaling pathway (vascular endothelial growth factor A \[VEGFA\] and microtu-bule associated protein tau \[MAPT\]).

Significant function and pathways related to miRNA targets
----------------------------------------------------------

The target genes of upregulated miRNAs were significantly enriched in 30 pathways, such as the oxytocin signaling pathway, AMPK signaling pathway, and Fc gamma R-mediated phagocytosis. The downregulated miRNAs were significantly enriched in 67 pathways, such as gap junction, estrogen signaling pathway, and prolactin signaling pathway. The top 20 significant pathways for miRNA--target genes are shown in [Figure 3](#f3-cia-13-2407){ref-type="fig"}.

With the criterion for significance set as *P*\<0.05, 70 GO-BP terms were found to be closely related to gene targets of upregulated miRNAs, while 143 GO functions were related to target genes of downregulated miRNAs. As shown in [Figure 4](#f4-cia-13-2407){ref-type="fig"}, the top 20 significant BP terms for upregulated miRNAs included the regulation of synaptic vesicle exocytosis, Notch signaling pathway, and histone deacetylation.

The top 20 significant BP terms for downregulated miRNAs comprised the regulation of ventricular cardiac muscle cell membrane, response to muscle stretch, and cardiac muscle cell action potential involved in contraction.

PPI network and module analysis
-------------------------------

A PPI network of target genes was constructed with 1,291 edges connecting with 414 nodes. On the basis of score of \>10, three significant modules were screened, including module-a (score =22, containing 15 nodes and 105 edges), module-b (score =15, containing 15 nodes and 105 edges), and module-c (score =12, containing 12 nodes and 66 interaction pairs; [Figure 5](#f5-cia-13-2407){ref-type="fig"}).

Genes in module-a were significantly enriched in two pathways, including ubiquitin-mediated proteolysis and circadian rhythm. Similarly, two pathways were closely related to module-b genes, including endocytosis and synaptic vesicle cycle. A total of 36 pathways were significantly enriched by module-c genes, such as retrograde endocannabinoid signaling, glutamatergic synapse, ovarian steroidogenesis, and regulation of lipolysis in adipocytes ([Table 3](#t3-cia-13-2407){ref-type="table"}).

TF regulatory network
---------------------

A total of 344 TF--target gene regulatory interactions were predicted, including 58 upregulated miRNA--target genes, 149 downregulated miRNA--target genes, and 2 TFs (early growth response 1 \[EGR1\] and nanos C2HC-type zinc finger 1 \[NANOS1\]; [Figure 6](#f6-cia-13-2407){ref-type="fig"}).

Subjects
--------

Subjects (two females and three males) with a mean age of 37.6±14.5 years were included in the control group for fractures. The gender-paired patients with a mean age of 82.4±3.3 years were included in the patient group.

RT-qPCR validation
------------------

The expression of has-miR-19a-3p, has-miR-144-3p, has-miR-34a-5p, and has-miR-449b-5p were measured by PCR analysis. Results showed that the expression of has-miR-34a-5p and has-miR-449b-5p was significantly higher in the patient group than in the control group, which was consistent with the analysis described earlier (*P*\<0.01). There was no significant difference in the expression of has-miR-19a-3p and has-miR-144-3p between the two groups, which was not consistent with the bioinformatic prediction ([Figure 7](#f7-cia-13-2407){ref-type="fig"}).

Furthermore, the expression of key target genes involved in cellular senescence (SIRT1 and CDC25A), MAPK sig-naling pathway (VEGFA and MAPT), and AMPK signaling pathway (PRKAA1 and PFKFB3) was also detected. Results showed that the expression levels of SIRT1, VEGFA, PRKAA1, and PFKFB3 were significantly increased in the patient group compared to that in the control group (*P*\<0.05); however, CDC25A and MAPT expression did not exhibit significant difference between the two groups ([Figure 8](#f8-cia-13-2407){ref-type="fig"}).

Discussion
==========

The role of miRNAs in regulating the aging process has not yet been elucidated. In a previous study, the microarray data (GSE23527) were generated to analyze differentially expressed miRNAs in aging human skeletal muscle, followed by the identification of key cellular functions and canonical pathways related to the progression of muscle loss with aging (sarcopenia) based on ingenuity pathway analysis; the results showed that aging is characterized by an enhanced expression of Let-7 family members that may downregulate genes related to cellular proliferation.[@b15-cia-13-2407] Compared to this study, we downloaded this microarray data and also identified the differentially expressed miRNAs between young and old skeletal muscles. Furthermore, function and pathway enrichment analyses were also performed. In addition to these, we conducted other analyses, such as PPI network and TF prediction for target genes. These comprehensive analyses will help us identify more significant miRNAs. The results suggested that a total of 23 miRNAs were differentially expressed in old muscle samples, among which 12 were involved in the miRNA--target gene network.

Pathway analysis showed that the gene targets of upregulated miRNAs were significantly enriched in the AMPK signaling pathway. It is reported that AMPK plays a key role in controlling the aging process by regulating energy metabolism, autophagic degradation, and stress resistance.[@b27-cia-13-2407] AMPK can improve cellular stress resistance and play a critical role in suppressing cell aging. The loss of AMPK activation increased cell stress and suppressed autophagic clearance, which contributed to the cell aging process.[@b27-cia-13-2407] Another study found that the activation of AMPK signaling was reduced in the skeletal muscles of old rats, suggesting that AMPK activation reduction was a contributory factor in aging process.[@b28-cia-13-2407] Furthermore, it is reported that deletion of muscle-specific PRKAA1 may lead to delayed development of skeletal muscles and regulate lipid metabolism and mitochondrial oxidation in mice fed a high-fat diet, suggesting that PRKAA1 may be involved in related metabolic diseases.[@b29-cia-13-2407] In this study, has-miR-19a, with a degree of 434, was the most significant node in the miRNA--target gene network. Pathway analysis also showed that has-miR-19a was closely related to the AMPK signaling pathway. The expression of PRKAA1 and PFKFB3 involved in the AMPK signaling pathway was significantly increased in the patients with sarcopenia. All these indicated that AMPK signaling played a critical role in muscle aging process involved with has-miR-19a. hsa-miR-34a, with a degree of 217, was another significant node in the miRNA--target gene network. Pathway analysis indicated that has-miR-34a was significantly enriched in cellular senescence and MAPK signaling pathway. It is reported that cellular senescence may be involved in the aging process via the accumulation of senescent cells and stem cell loss.[@b30-cia-13-2407] Cellular senescence may be a marker for the aging process, suggesting that the pathway results were significant. In addition, MAPK plays a critical role in regulating stress responses in skeletal muscles. The activation of MAPK can be induced by exercise, which is involved in preventing skeletal muscle atrophy.[@b31-cia-13-2407] p38 MAPK signaling pathway affects the autonomous loss and renewal of stem cells.[@b32-cia-13-2407] The satellite cell homeostatic process was dysregulated by p38 MAPK signaling in the skeletal muscles of aged mice.[@b32-cia-13-2407] Moreover, we found that the expression levels of SIRT1 involved in cellular senescence and VEGFA involved in MAPK signaling pathway were significantly increased in patients with sarcopenia. Aging gastric mucosa has significantly reduced the expression of VEGF, hinting the role of VEGF in aging-related impairment of angiogenesis.[@b33-cia-13-2407] Mohamed et al[@b34-cia-13-2407] revealed that the activation of SIRT1 ameliorated skeletal muscle performance in pathophysiological conditions such as sarcopenia and disuse-induced atrophy in aging mice. Liao et al[@b35-cia-13-2407] demonstrated that exercise, resveratrol, or their combination played a protective role in sarcopenia in aged rats through regulating AMPK/SIRT1 pathway. These observations suggest that our findings are significant.

Furthermore, in this study, hsa-miR-34a was also found to be closely related to endocrine resistance. It is found that the secondary hormones underlying insulin-like signaling may be involved in the regulation of aging in nematodes and flies.[@b36-cia-13-2407] In all species, the endocrine system plays a key role in modulating the aging process. Although insulin resistance was found to accelerate muscle protein degradation, which causes muscle atrophy in old people, whether the endocrine system manipulated the aging process by insulin-like signaling remained to be ascertained. Thus, endocrine resistance may be an important event in the aging process regulated by hsa-miR-34a. Further studies are warranted in the future.

However, some limitations merit further consideration. First, whether the identified differentially expressed miRNAs can be used as muscle-specific miRNAs is still needed to be confirmed by more signature analysis. Second, our patient sample size was small, which might influence the stability of statistical power. More than five patient samples are required to be collected for validation of our results. Third, we detected the expression of four miRNAs in skeletal muscle from sarcopenic patients and control subjects. Nevertheless, the connection between aging and sarcopenia in this context was not investigated. In addition, the information on muscle mass or strength in relation to their original analysis was not provided, which hindering us for further patient analysis. Therefore, additional experiments and high throughput data are needed to confirm our findings.

Conclusion
==========

miRNAs play regulatory roles in the aging process of skeletal muscles. AMPK signaling pathway, cellular senescence, and MAPK signaling pathway are significant pathways in the aging process. has-miR-19a and hsa-miR-34a, as significant nodes in miRNA regulatory network, may provide new perspectives to prevent muscle aging.
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![miRNA--target gene regulatory network.\
**Notes:** Red triangle represents the upregulated miRNAs, green arrow represents the downregulated miRNAs, and blue circle represents the target genes. The black line with arrows indicates the interaction between miRNAs and target genes.](cia-13-2407Fig1){#f1-cia-13-2407}

![The significant pathways related to miRNAs.\
**Notes:** (**A**) For upregulated miRNAs. (**B**) For downregulated miRNAs.\
**Abbreviations:** DCM, dilated cardiomyopathy; IBD, inflammatory bowel disease.](cia-13-2407Fig2){#f2-cia-13-2407}

![Top 20 significant pathways enriched by gene targets.\
**Notes:** (**A**) Results of upregulated miRNAs. (**B**) Results of downregulated miRNAs.](cia-13-2407Fig3){#f3-cia-13-2407}

![Top 20 biological processes enriched by target genes.\
**Notes:** (**A**) Results of upregulated miRNAs. (**B**) Results of downregulated miRNAs.\
**Abbreviation:** GO, Gene Ontology.](cia-13-2407Fig4){#f4-cia-13-2407}

![PPI network of target genes.\
**Notes:** Green rhombus nodes represent the target genes of downregulated miRNAs. Red circular nodes represent the target genes of upregulated miRNAs. The edges indicate the interaction between target genes.\
**Abbreviation:** PPI, protein--protein interaction.](cia-13-2407Fig5){#f5-cia-13-2407}

![TF regulatory network.\
**Notes:** Green, downregulated miRNAs. Red, upregulated miRNAs. Yellow, TFs.\
**Abbreviation:** TF, transcriptional factor.](cia-13-2407Fig6){#f6-cia-13-2407}

![RT-qPCR analyzed the expression of has-miR-19a-3p, has-miR-144-3p, has-miR-34a-5p, and has-miR-449b-5p.\
**Notes:** (**A**) The relative expression of has-miR-19a. (**B**) The relative expression of has-miR-144. (**C**) The relative expression of has-miR-34a. (**D**) The relative expression of has-miR-449b. ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001.\
**Abbreviation:** RT-qPCR, real-time quantitative PCR.](cia-13-2407Fig7){#f7-cia-13-2407}

![The expression of key target genes involved in cellular senescence (SIRT1 and CDC25A), MAPK signaling pathway (VEGFA and MAPT), and AMPK signaling pathway (PRKAA1 and PFKFB3).\
**Notes:** (**A**) The relative expression of SITR1. (**B**) The relative expression of CDC25A. (**C**) The relative expression of VEGFA. (**D**) The relative expression of MAPT. (**E**) The relative expression of PRKAA1. (**F**) The relative expression of PFKFB3. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01.](cia-13-2407Fig8){#f8-cia-13-2407}

###### 

Primer sequences for PCR analysis

  Symbol                   Sequences (5′--3′)
  ------------------------ ------------------------------------------------------
                           
  Human-U6-RT              GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATATG
  General reverse primer   GTGCAGGGTCCGAGGT
  hsa-miR-19a-3p-RT        GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAGTT
  hsa-miR-144-3p-RT        GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGTACA
  hsa-miR-34a-5p-RT        GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAACC
  has-miR-532-5p-RT        GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACGGTC
  hsa-miR-449b-5p-RT       GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCCAGC
  JH-hsa-miR-19a-3p-F      GCGCTGTGCAAATCTATGCAA
  JH-hsa-miR-144-3p-F      GCGCGCTACAGTATAGATGA
  JH-hsa-miR-34a-5p-F      GCTGGCAGTGTCTTAGCT
  JH-has-miR-532--5p-F     GCCATGCCTTGAGTGTAG
  JH-hsa-miR-449b-5p-F     GCGCAGGCAGTGTATTGTTA

###### 

Differentially expressed miRNAs

  GSE23527-GPL10358                                          GSE23527-GPL10415                                                                                     
  ---------------------------------------------------------- ------------------- ---------- --------------------------------------------------------- ------------ ----------
                                                                                                                                                                   
  hsa-miR-450a                                               1.513142            9.77E-05   hsa-miR-34a                                               1.9387314    0.000656
  hsa-miR-16-2[\*](#tfn1-cia-13-2407){ref-type="table-fn"}   1.183442            1.66E-03   hsa-miR-548j                                              1.4707223    0.001875
  hsa-miR-215                                                1.153009            4.86E-04   hsa-miR-933                                               1.1785806    0.001847
  hsa-miR-184                                                1.093055            9.16E-04   hsa-miR-449b                                              1.164987     0.003803
  hsa-miR-374b[\*](#tfn1-cia-13-2407){ref-type="table-fn"}   1.090489            8.31E-04   hsa-miR-499-5p                                            1.1096546    0.00423
  hsa-miR-15b[\*](#tfn1-cia-13-2407){ref-type="table-fn"}    1.017695            3.81E-03   hsa-miR-1271                                              −1.0073725   0.006553
  hsa-miR-500[\*](#tfn1-cia-13-2407){ref-type="table-fn"}    −1.021664           1.65E-03   hsa-miR-1303                                              −1.2463053   0.009014
  hsa-miR-24-2[\*](#tfn1-cia-13-2407){ref-type="table-fn"}   −1.034437           3.63E-04   hsa-miR-7-2[\*](#tfn1-cia-13-2407){ref-type="table-fn"}   −1.2652065   0.000861
  hsa-miR-362-5p                                             −1.083984           4.29E-03   hsa-miR-365                                               −1.3649855   0.008124
  hsa-miR-487b                                               −1.097873           4.66E-05   hsa-miR-19a                                               −1.6839475   0.006358
  hsa-miR-532-5p                                             −1.161705           1.66E-04   hsa-miR-144                                               −2.5983958   0.000196
  hsa-miR-362-3p                                             −1.196579           8.39E-04                                                                          

**Note:**

Indicates the miRNA with lower expression level.

**Abbreviations:** FC, fold change. In general, the two arms of a miRNA precursor are likely to produce two mirnas separately.

###### 

Significant pathways that enriched by module genes

                                                              KEGG pathway                                    Count      *P*-value                            Genes
  ----------------------------------------------------------- ----------------------------------------------- ---------- ------------------------------------ -----------------------------------------------------
                                                                                                                                                              
  Module-a                                                    hsa04120:ubiquitin-mediated proteolysis         6          1.52E-07                             CUL5, UBE2D2, SOCS3, UBE3C, ITCH, FBXW11
                                                                                                                                                              
  hsa04710:circadian rhythm                                   2                                               3.53E-02   FBXW11, FBXL3                        
                                                                                                                                                              
  Module-b                                                    hsa04144:endocytosis                            8          6.30E-08                             EPS15, TFRC, ARRB2, IGF2R, AP2S1, RAB5A, CLTC, EPN2
  hsa04721:synaptic vesicle cycle                             4                                               1.50E-04   SYT1, AP2S1, VAMP2, CLTC             
  Module-c                                                    hsa04723:retrograde endocannabinoid signaling   5          5.12E-06                             ADCY1, ADCY7, ADCY9, CNR1, ADCY6
  hsa04724:glutamatergic synapse                              5                                               8.31E-06   ADCY1, ADCY7, ADCY9, GRM7, ADCY6     
  hsa04913:ovarian steroidogenesis                            4                                               2.73E-05   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04923:regulation of lipolysis in adipocytes              4                                               4.09E-05   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04062:chemokine signaling pathway                        5                                               5.76E-05   ADCY1, ADCY7, ADCY9, ADCY6, CXCL12   
  hsa04976:bile secretion                                     4                                               7.67E-05   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04918:thyroid hormone synthesis                          4                                               8.01E-05   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04971:gastric acid secretion                             4                                               9.08E-05   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04015:Rap1 signaling pathway                             5                                               9.27E-05   ADCY1, ADCY7, ADCY9, CNR1, ADCY6     
  hsa04925:aldosterone synthesis and secretion                4                                               1.24E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa05414:dilated cardiomyopathy                             4                                               1.38E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04727:GABAergic synapse                                  4                                               1.43E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04911:insulin secretion                                  4                                               1.43E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04970:salivary secretion                                 4                                               1.48E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04914:progesterone-mediated oocyte maturation            4                                               1.53E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04540:gap junction                                       4                                               1.59E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04912:GnRH signaling pathway                             4                                               1.75E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa05032:morphine addiction                                 4                                               1.75E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04972:pancreatic secretion                               4                                               1.87E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04713:circadian entrainment                              4                                               1.99E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04750:inflammatory mediator regulation of TRP channels   4                                               2.18E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04915:estrogen signaling pathway                         4                                               2.25E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04916:melanogenesis                                      4                                               2.32E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04114:oocyte meiosis                                     4                                               2.99E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04725:cholinergic synapse                                4                                               3.16E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04270:vascular smooth muscle contraction                 4                                               3.88E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04611:platelet activation                                4                                               5.03E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04261:adrenergic signaling in cardiomyocytes             4                                               7.07E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04921:oxytocin signaling pathway                         4                                               8.90E-04   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04022:cGMP-PKG signaling pathway                         4                                               1.03E-03   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa05200:pathways in cancer                                 5                                               1.03E-03   ADCY1, ADCY7, ADCY9, ADCY6, CXCL12   
  hsa00230:purine metabolism                                  4                                               1.22E-03   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04024:cAMP signaling pathway                             4                                               1.71E-03   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa05166:HTLV-I infection                                   4                                               3.58E-03   ADCY1, ADCY7, ADCY9, ADCY6           
  hsa04080:neuroactive ligand--receptor interaction           4                                               4.47E-03   S1PR1, NMUR2, GRM7, CNR1             
  hsa04020:calcium signaling pathway                          3                                               2.13E-02   ADCY1, ADCY7, ADCY9                  

**Abbreviations:** KEGG, Kyoto Encyclopedia of Genes and Genomes; TRP, transient receptor potential.
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